Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was downgraded by stock analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday. They currently have a $146.51 target price on the biopharmaceutical company’s stock. Vetr‘s price target would indicate a potential upside of 5.27% from the stock’s previous close. A number […]
